Tao Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tao Wu has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Xianli He
Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China
5 shared publications Bo Zhang
Department of General Surgery, Gastrointestinal Surgery Center, Tangdu Hospital, The Fourth Military Medical University, Xi’an, China
4 shared publications- Nan Wang
Department of General Surgery, Tangdu Hospital, the Air Force Medical University, Xi’an, China
4 shared publications Ying Yang
Department of General Surgery, Tangdu Hospital, the Air Force Medical University, Xi’an, China
3 shared publicationsJiaxing He
Department of General Surgery, Tangdu Hospital, the Air Force Medical University, Xi’an, China
2 shared publicationsShiqi Liu
Department of General Surgery, Gastrointestinal Surgery Center, Tangdu Hospital, The Fourth Military Medical University, Xi’an, China
2 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1) , 1139
Comparative effectiveness of neoadjuvant therapy combined with stent placement versus stent alone in obstructive colorectal cancer: a multicenter retrospective analysis
Objective: The aim of this study was to evaluate the impact of self-expandable metal stents (SEMS) and neoadjuvant therapy (NAT) for obstructive colorectal cancer (CRC). Methods: This multicenter, retrospective study analyzed 154 patients with obstructive CRC from three centers between 2011 and 2025. Patients were allocated to either a NAT combined with SEMS group ( n = 93) or a SEMS-alone group ( n = 61). Short-term procedural outcomes, pathological tumor response, long-term survival, and the impact of the time interval from stenting to surgery were evaluated between groups and across two time periods (2011–2020 vs. 2021–2025). Results: Baseline characteristics were largely comparable between groups. The NAT group demonstrated significantly lower intraoperative stoma rates (8.6% vs. 29.0%, P = 0.031) and postoperative complication rates (8.6% vs. 29.0%, P = 0.031) in the 2011–2020, advantages that persisted in the 2021–2025. Pathological assessment revealed a superior tumor response in the 2021–2025, with 20.7% achieving TRG 0–1 and significantly higher rates of T and N downstaging (39.7% and 60.3%) compared to the 2011–2020. Although survival benefits were not significant in the 2011–2020 period, NAT may be associated with a significant improvement in overall survival (OS) in the 2021–2025 cohort ( P = 0.013). Analysis of surgical timing identified an optimal interval of 14–21 days related to OS for the SEMS group, whereas for NAT patients, an interval exceeding 90 days was associated with worse disease-free survival (DFS). Conclusion: SEMS-NAT for obstructive CRC may is an important factor for improved surgical quality and OS benefit in 2021–2025. This study provides crucial evidence for optimizing treatment strategy by recommending a surgery interval.
- 24 September 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1) , 1139
Open AccessComparative effectiveness of neoadjuvant therapy combined with stent placement versus stent alone in obstructive colorectal cancer: a multicenter retrospective analysis
Objective: The aim of this study was to evaluate the impact of self-expandable metal stents (SEMS) and neoadjuvant therapy (NAT) for obstructive colorectal cancer (CRC). Methods: This multicenter, retrospective study analyzed 154 patients with obstructive CRC from three centers between 2011 and 2025. Patients were allocated to either a NAT combined with SEMS group ( n = 93) or a SEMS-alone group ( n = 61). Short-term procedural outcomes, pathological tumor response, long-term survival, and the impact of the time interval from stenting to surgery were evaluated between groups and across two time periods (2011–2020 vs. 2021–2025). Results: Baseline characteristics were largely comparable between groups. The NAT group demonstrated significantly lower intraoperative stoma rates (8.6% vs. 29.0%, P = 0.031) and postoperative complication rates (8.6% vs. 29.0%, P = 0.031) in the 2011–2020, advantages that persisted in the 2021–2025. Pathological assessment revealed a superior tumor response in the 2021–2025, with 20.7% achieving TRG 0–1 and significantly higher rates of T and N downstaging (39.7% and 60.3%) compared to the 2011–2020. Although survival benefits were not significant in the 2011–2020 period, NAT may be associated with a significant improvement in overall survival (OS) in the 2021–2025 cohort ( P = 0.013). Analysis of surgical timing identified an optimal interval of 14–21 days related to OS for the SEMS group, whereas for NAT patients, an interval exceeding 90 days was associated with worse disease-free survival (DFS). Conclusion: SEMS-NAT for obstructive CRC may is an important factor for improved surgical quality and OS benefit in 2021–2025. This study provides crucial evidence for optimizing treatment strategy by recommending a surgery interval.
- Open Access
- 1 July 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-13
SLC44A2 negatively regulates mitochondrial fatty acid oxidation to suppress colorectal progression by blocking the MUL1-CPT2 interaction
The dependence of cancer cells on mitochondrial metabolism has been revealed in various cancer types. However, the mechanisms underlying this metabolic remodeling remain largely unclear. Solute carrier family 44 member 4 (SLC44A2) is a mitochondrial membrane-localized transmembrane protein belonging to the choline transporter-like protein family. Recently, it was reported that deletion of SLC44A2 impairs adhesion and increases proliferation in cultured lung mesenchymal cells. This finding implies that SLC44A2 may play a role in the malignant phenotypes of human cancers. However, the effects of SLC44A2 on malignant phenotypes and mitochondrial metabolism in human cancers remain unexplored. In the present investigation, we observed a significant reduction in SLC44A2 expression in colorectal cancer (CRC), and low SLC44A2 expression was closely associated with poorer survival of CRC patients. Functional assays demonstrated that SLC44A2 suppressed CRC growth and metastasis both in vitro and in vivo. Mechanistically, SLC44A2 inhibits mitochondrial fatty acid oxidation, thereby reducing energy supply and increase ROS stress. This effect is achieved by promoting mitochondrial E3 ubiquitin ligase 1 (MUL1)-regulated degradation of carnitine palmitoyltransferase 2 (CPT2) via enhancing the interaction between MUL1 and CPT2, without increasing MUL1 expression, which ultimately contributes to the proliferation and metastasis of CRC. Together, SLC44A2 functions as a critical tumor suppressor in CRC and potential therapeutic target in the treatment of this malignancy.
- 1 July 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-13
Open AccessSLC44A2 negatively regulates mitochondrial fatty acid oxidation to suppress colorectal progression by blocking the MUL1-CPT2 interaction
The dependence of cancer cells on mitochondrial metabolism has been revealed in various cancer types. However, the mechanisms underlying this metabolic remodeling remain largely unclear. Solute carrier family 44 member 4 (SLC44A2) is a mitochondrial membrane-localized transmembrane protein belonging to the choline transporter-like protein family. Recently, it was reported that deletion of SLC44A2 impairs adhesion and increases proliferation in cultured lung mesenchymal cells. This finding implies that SLC44A2 may play a role in the malignant phenotypes of human cancers. However, the effects of SLC44A2 on malignant phenotypes and mitochondrial metabolism in human cancers remain unexplored. In the present investigation, we observed a significant reduction in SLC44A2 expression in colorectal cancer (CRC), and low SLC44A2 expression was closely associated with poorer survival of CRC patients. Functional assays demonstrated that SLC44A2 suppressed CRC growth and metastasis both in vitro and in vivo. Mechanistically, SLC44A2 inhibits mitochondrial fatty acid oxidation, thereby reducing energy supply and increase ROS stress. This effect is achieved by promoting mitochondrial E3 ubiquitin ligase 1 (MUL1)-regulated degradation of carnitine palmitoyltransferase 2 (CPT2) via enhancing the interaction between MUL1 and CPT2, without increasing MUL1 expression, which ultimately contributes to the proliferation and metastasis of CRC. Together, SLC44A2 functions as a critical tumor suppressor in CRC and potential therapeutic target in the treatment of this malignancy.
- Open Access
- 17 January 2022
- Published by Springer Nature in Oncogenesis
- Vol. 11 (1) , 1-11
EDDM3A drives gastric cancer progression by promoting HIF-1α-dependent aerobic glycolysis
Epididymal protein 3A (EDDM3A) is a protein involved in sperm maturation. It has been demonstrated that EDDM3A expression is upregulated and promotes cell proliferation in non-small cell lung cancer (NSCLC). However, the role of EDDM3A in other types of human cancers, including gastric cancer (GC), is still unexplored. Here, we show that the expression of EDDM3A is significantly upregulated in gastric cancer (GC) tissues and its upregulation correlates with poorer survival in patients with gastric cancer. Knockdown of EDDM3A inhibited growth and metastasis of GC cells, whereas overexpression of EDDM3A exhibited the opposite effect. Mechanistically, enhanced aerobic glycolysis mediated by upregulation of HIF-1α and subsequently increased target glycolytic genes and decreased mitochondrial biogenesis was found to contribute to the promotion of tumor growth and metastasis by EDDM3A in GC cells. Additionally, upregulation of EDDM3A in GC is at least partially mediated by downregulation of miR-618. In conclusion, elevated EDDM3A plays a pivotal oncogenic role in gastric carcinogenesis, suggesting it as a potential therapeutic target for treatment of GC.
- 17 January 2022
- Published by Springer Nature in Oncogenesis
- Vol. 11 (1) , 1-11
Open AccessEDDM3A drives gastric cancer progression by promoting HIF-1α-dependent aerobic glycolysis
Epididymal protein 3A (EDDM3A) is a protein involved in sperm maturation. It has been demonstrated that EDDM3A expression is upregulated and promotes cell proliferation in non-small cell lung cancer (NSCLC). However, the role of EDDM3A in other types of human cancers, including gastric cancer (GC), is still unexplored. Here, we show that the expression of EDDM3A is significantly upregulated in gastric cancer (GC) tissues and its upregulation correlates with poorer survival in patients with gastric cancer. Knockdown of EDDM3A inhibited growth and metastasis of GC cells, whereas overexpression of EDDM3A exhibited the opposite effect. Mechanistically, enhanced aerobic glycolysis mediated by upregulation of HIF-1α and subsequently increased target glycolytic genes and decreased mitochondrial biogenesis was found to contribute to the promotion of tumor growth and metastasis by EDDM3A in GC cells. Additionally, upregulation of EDDM3A in GC is at least partially mediated by downregulation of miR-618. In conclusion, elevated EDDM3A plays a pivotal oncogenic role in gastric carcinogenesis, suggesting it as a potential therapeutic target for treatment of GC.
- Open Access
- 27 November 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (12) , 1-9
SLC25A1 promotes tumor growth and survival by reprogramming energy metabolism in colorectal cancer
Abnormal lipid metabolism has been commonly observed in various human cancers, including colorectal cancer (CRC). The mitochondrial citrate carrier SLC25A1 (also known as mitochondrial citrate/isocitrate carrier, CIC), has been shown to play an important role in lipid metabolism regulation. Our bioinformatics analysis indicated that SLC25A1 was markedly upregulated in CRC. However, the role of SLC25A1 in the pathogenesis and aberrant lipid metabolism in CRC remain unexplored. Here, we found that SLC25A1 expression was significantly increased in tumor samples of CRC as compared with paired normal samples, which is associated with poor survival in patients with CRC. Knockdown of SLC25A1 significantly inhibited the growth of CRC cells by suppressing the progression of the G1/S cell cycle and inducing cell apoptosis both in vitro and in vivo, whereas SLC25A1 overexpression suppressed the malignant phenotype. Additionally, we demonstrated that SLC25A1 reprogrammed energy metabolism to promote CRC progression through two mechanisms. Under normal conditions, SLC25A1 increased de novo lipid synthesis to promote CRC growth. During metabolic stress, SLC25A1 increased oxidative phosphorylation (OXPHOS) to protect protects CRC cells from energy stress-induced cell apoptosis. Collectively, SLC25A1 plays a pivotal role in the promotion of CRC growth and survival by reprogramming energy metabolism. It could be exploited as a novel diagnostic marker and therapeutic target in CRC.
- 27 November 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (12) , 1-9
Open AccessSLC25A1 promotes tumor growth and survival by reprogramming energy metabolism in colorectal cancer
Abnormal lipid metabolism has been commonly observed in various human cancers, including colorectal cancer (CRC). The mitochondrial citrate carrier SLC25A1 (also known as mitochondrial citrate/isocitrate carrier, CIC), has been shown to play an important role in lipid metabolism regulation. Our bioinformatics analysis indicated that SLC25A1 was markedly upregulated in CRC. However, the role of SLC25A1 in the pathogenesis and aberrant lipid metabolism in CRC remain unexplored. Here, we found that SLC25A1 expression was significantly increased in tumor samples of CRC as compared with paired normal samples, which is associated with poor survival in patients with CRC. Knockdown of SLC25A1 significantly inhibited the growth of CRC cells by suppressing the progression of the G1/S cell cycle and inducing cell apoptosis both in vitro and in vivo, whereas SLC25A1 overexpression suppressed the malignant phenotype. Additionally, we demonstrated that SLC25A1 reprogrammed energy metabolism to promote CRC progression through two mechanisms. Under normal conditions, SLC25A1 increased de novo lipid synthesis to promote CRC growth. During metabolic stress, SLC25A1 increased oxidative phosphorylation (OXPHOS) to protect protects CRC cells from energy stress-induced cell apoptosis. Collectively, SLC25A1 plays a pivotal role in the promotion of CRC growth and survival by reprogramming energy metabolism. It could be exploited as a novel diagnostic marker and therapeutic target in CRC.
- 7 June 2011
- Published by Wiley in Journal of Surgical Oncology
- Vol. 104 (7) , 787-791
Identification of high‐risk stage II and stage III colorectal cancer by analysis of MMP‐21 expression
Background The expression of matrix metalloproteinase‐21 (MMP‐21) has been shown to be elevated in some solid tumor and thought to enhance tumor invasion and metastasis ability. In the present study, we investigated the expression of MMP‐21 and its association with prognosis in stage II and III colorectal cancer. Methods MMP‐21 expression was investigated in 286 cases of colorectal cancer by immunohistochemistry assay. Statistical analysis was utilized to evaluate the association of MMP‐21 expression with clinicopathological characters and overall survival of patients with stage II and III colorectal cancer. Results MMP‐21 expression was significantly higher in colorectal cancer, compared with that in normal epithelial tissue. And it also correlated with tumor invasion, lymph node metastasis, and distant metastasis of colorectal cancer. MMP‐21 was also proved to be an independent prognostic factor in patients with stage II as well as stage III colorectal cancer. However, no correlations between MMP‐21 expression and patients' age, sex, tumor location, or differentiation status were detected. Conclusion These results suggested the potential role of MMP‐21 in the invasion and metastasis process of human colorectal cancer. It could also be a novel molecular marker to predict prognosis of patients with stage II and stage III colorectal cancer. J. Surg. Oncol. 2011; 104:787–791.
- 7 June 2011
- Published by Wiley in Journal of Surgical Oncology
- Vol. 104 (7) , 787-791
Identification of high‐risk stage II and stage III colorectal cancer by analysis of MMP‐21 expression
Background The expression of matrix metalloproteinase‐21 (MMP‐21) has been shown to be elevated in some solid tumor and thought to enhance tumor invasion and metastasis ability. In the present study, we investigated the expression of MMP‐21 and its association with prognosis in stage II and III colorectal cancer. Methods MMP‐21 expression was investigated in 286 cases of colorectal cancer by immunohistochemistry assay. Statistical analysis was utilized to evaluate the association of MMP‐21 expression with clinicopathological characters and overall survival of patients with stage II and III colorectal cancer. Results MMP‐21 expression was significantly higher in colorectal cancer, compared with that in normal epithelial tissue. And it also correlated with tumor invasion, lymph node metastasis, and distant metastasis of colorectal cancer. MMP‐21 was also proved to be an independent prognostic factor in patients with stage II as well as stage III colorectal cancer. However, no correlations between MMP‐21 expression and patients' age, sex, tumor location, or differentiation status were detected. Conclusion These results suggested the potential role of MMP‐21 in the invasion and metastasis process of human colorectal cancer. It could also be a novel molecular marker to predict prognosis of patients with stage II and stage III colorectal cancer. J. Surg. Oncol. 2011; 104:787–791.